Clinical trials: Gut Microbiota Modulation
Melanoma (Skin), Melanoma
Pembrolizumab and EDP1503 in Advanced Melanoma
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
- Trial name
- NCT03595683
- Testing
- Pembrolizumab, EDP1503
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Obesity
Modulation of the Intestinal Microbiome by a High Protein Diet
The objective of this study is to test and determine whether a high protein diet induces weight loss by modulating the composition and function of the intestinal microbiome in obesity.
- Trial name
- HPD (NCT04812964)
- Testing
- Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass, Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Nonalcoholic Fatty Liver Disease, NAFLD
Rifaximin in Fatty Liver Disease
TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in Non-Alcoholic Steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis
- Trial name
- RiFL (NCT01355575)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Intestinal Microbiota and Barrier Function
Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults
This study evaluates the effect of a dietary supplement to improve gut health. The participants will take one of six dietary treatments for three weeks, and the gut bacteria and the gut intestinal barrier will be assessed to…
- Trial name
- NCT02355210
- Testing
- Bifidobacteria adolescentis BD1, Bifidobacteria animalis subsp. lactis BB-12, Bifidobacteria adolescentis BD1 and galactooligosaccharide
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
Ulcerative Colitis
Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis
This study aims to characterize the changes on intestinal microbiota pattern associated with the use of golimumab in order to determine if intestinal microbiota markers may correlate with golimumab therapeutic effect in patients…
- Trial name
- GOLI2015 (NCT03018925)
- Testing
- Golimumab
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta